High-flux versus low-flux membranes for end-stage kidney disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2012, Pages

  Palmer, Suetonia C ^a   Rabindranath, Kannaiyan S ^b   Craig, Jonathan C ^c,d   Roderick, Paul J ^e   Locatelli, Francesco ^f   Strippoli, Giovanni FM ^d,g,h,i  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Waikato Public Hospital   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f A MANZONI HOSPITAL   (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h Medical Scientific Office   (Sweden)

ⁱ Diaverum Academy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL MEMBRANE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 84873034821     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005016.pub2     Document Type: Review

References (379)

1. Acchiardo SR, Quinn BP, Burk LB, Moore LW. Are high flux dialysis and erythropoietin treatment in a collision course?. ASAIO Transactions 1989;35(3):308-10. [MEDLINE: 2688711]
2. Ayli D, Ayli M, Azak A, Yuksel C, Kosmaz GP, Atilgan G, et al. The effect of high-flux hemodialysis on renal anemia. Journal of Nephrology 2004;17(5):701-6. [MEDLINE: 15593038]
3. Ayli M, Ayli D, Azak A, Yuksel C, Atilgan G, Dede F, et al. The effect of high-flux hemodialysis on dialysis-associated amyloidosis. Renal Failure 2005;27(1):31-4. [MEDLINE: 15717632]
4. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. Journal of the American Society of Nephrology 1995;5(9):1703-8. [MEDLINE: 7780060]
5. Brown EA, Sethi D, Perkin GD, Maini RN, Gower PE. High flux haemodialysis: optimal treatment for dialysis arthropathy? [abstract]. Kidney International 1989;35:241.
6. Sethi D, Brown EA, Perkin GD, Maini RN, Gower PE. High-flux haemodialysis: optimal treatment for dialysis arthropathy? [abstract]. Nephrology Dialysis Transplantation 1989;4(4):318.
7. Chu P, Chiu Y, Lin J, Chen S, Wu K. The effect of low-flux and high-flux dialysers on endothelial dysfunction, oxidative stress and insulin resistance [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):738A.
8. Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD. Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. [see comment]. Blood Purification 2008;26(2):213-20. [MEDLINE: 18285698]
9. Churchill DN, Bird DR, Taylor DW, Beecroft ML, Gorman J, Wallace JE. Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. American Journal of Nephrology 1992;12(6):412-8. [MEDLINE: 1292340]
10. Churchill DN, Taylor DW, Tomlinson CW, Beecroft ML, Gorman J, Stanton E. Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 1993;65(4):573-577. [MEDLINE: 8302412]
11. Collins D, Lambert M, Tannenbaum J, Oliverio M, Schwab S. Tolerance of hemodialysis: a randomized prospective trial of high flux vs. conventional high efficiency hemodialysis [abstract]. Journal of the American Society of Nephrology 1992;3(3):360. [CENTRAL: CN-00460571]
12. Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ. Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis. Journal of the American Society of Nephrology 1993;4(2):148-54. [MEDLINE: 8400077]
13. De Vriese AS, Langlois M, Bernard D, Geerolf I, Stevens L, Boelaert JR, et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrology Dialysis Transplantation 2003;18(12):2596-600. [MEDLINE: 14605283]
14. Fishbane S, Bucala R, Pereira BJG, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997;52(6):1645-50. [EMBASE: 1998021792]
15. Gardinali M, Calcagno A, Conciato L, Agostoni A, Rosti A, Cori P, et al. Complement activation in dialysis: effects on cytokines, lymphocyte activation and beta 2 microglobulin. International Journal of Artificial Organs 1994;17(6):337-44. [MEDLINE: 7806419]
16. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrology Dialysis Transplantation 1996;11(Suppl 2):104-7. [MEDLINE: 8804007]
17. Kaufman AM, Goldberg IJ, Lavarias VA, Vanni-Reyes T, Levin NW. High flux properties, not biocompatibility of dialysis membranes, improve cholesterol (chol) and triglyceride (tg) levels in patients with end stage renal disease (esrd) [abstract]. Journal of the American Society of Nephrology 1995;6(3):580. [CENTRAL: CN-00484602]
18. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. American Journal of Kidney Diseases 1997;30(3):366-73. [MEDLINE: 9292565]
19. Schiffl H, Hartmann J, Lang S. Bicompatible membranes slow the decline of residual renal function in patients undergoing regular hemodialysis [abstract]. Nephrology 1997;3(Suppl 1):S415. [CENTRAL: CN-00461676]
20. Benz RL, Pressman MR, Brown J. Does membrane flux (F) or dialysis eKT/V dose (K) affect ESRD-related sleep disorders in hemodialysis (HD) patients (Pts): an ancillary study of the HEMO trial [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program and Abstracts):20a.
21. Chelamcharla M, Yan G, Rocco M, Schulman G, Teehan B, Toto R, et al. Effect of hemodialysis dose and flux on lipoproteins (LP) in the HEMO study [abstract]. Nephrology 2005;10(Suppl):A285.
22. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, et al. Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. Journal of the Amercian Society of Nephrology 1999;10(1):117-27. [MEDLINE: 9890317]
23. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. Journal of the American Society of Nephrology 2003;14(12):3251-63. [MEDLINE: 14638924]
24. Cheung AK, Levin NW, HEMO Study Group. Effect of high flux (HF) hemodialysis (HD) membranes on clinical outcomes: results from the HEMO study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):432A.
25. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney International 2004;65(6):2380-9. [MEDLINE: 15149351]
26. Chumlea WC, Dwyer J, Bergen C, Burkart J, Paranandi L, Frydrych A, et al. Nutritional status assessed from anthropometric measures in the HEMO study. Journal of Renal Nutrition 2003;13(1):31-8. [MEDLINE: 12563621]
27. Daugirdas JT, Greene T, Cheung AK, Beck GJ, Levin NW, Kusek JW, et al. Effect of membrane flux intervention in HEMO study patients when grouped by months on dialysis at randomization, serum albumin, diabetes, and b2-M clearance [abstract]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):698A.
28. Delmez J, Beck G, Beddhu S, Levey A, Sarnak M, Yan G, et al. Effect of high flux hemodialysis (HD) on cerebrovascular (CBV) deaths: results from the HEMO study [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):609A.
29. Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G. Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose. American Journal of Kidney Diseases 1999;33(1):142-9. [MEDLINE: 9915282]
30. Depner TA, Gotch FA, Port FK, Wolfe RA, Lindsay RM, Blake PG, et al. How will the results of the HEMO study impact dialysis practice?. Seminars in Dialysis 2003;16(1):8-21. [MEDLINE: 12535292]
31. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine 2002;347(25):2010-9. [MEDLINE: 12490682]
32. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, et al. Design and statistical issues of the hemodialysis (HEMO) study. Controlled Clinical Trials 2000;21(5):502-25. [MEDLINE: 11018567]
33. Leypoldt JK, Cheung AK, Clark WR, Daugirdas JT, Gotch FA, Greene T, et al. Characterization of low and high flux dialyzers with reuse in the HEMO study: interim report [abstract]. Journal of the American Society of Nephrology 1996;7(9):1518.
34. Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine 2003;384(15):1491-4. [MEDLINE: 12691051]
35. Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis.[comment]. New England Journal of Medicine 2003;348(15):1491-4.
36. Maroni B, Burkhart J, Burrowes J, Dwyer J, Henry R, Kusek J, et al. Relationship between dialysis dose, membrane flux and indices of nutritional status at baseline in the HEMO study: an interm report [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):288A.
37. Rocco M, Dwyer J, HEMO Study Group. Effect of dose and flux interventions on nutritional parameters: results from the hemodialysis study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):421A.
38. Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney International 2004;65(6):2321-34. [MEDLINE: 15149346]
39. Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney International 2004;66(1):355-66. [MEDLINE: 15200444]
40. House A, Freeman D. Larger intradialytic effect of high flux vs low flux polysulfone on homocysteine levels, but not on lipids or apo AI/CIII ratio [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):209A.
41. House AA, Donnelly JG. Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. ASAIO Journal 1999;45(1):94-7. [MEDLINE: 9952016]
42. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Effect of high flux vs low flux hemodialysis on homocysteine, lipoprotein(a) and lipid profiles: a prospective randomized trial [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):211A. [CENTRAL: CN-00401331]
43. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrology Dialysis Transplantation 2000;15(7):1029-34. [MEDLINE: 10862642]
44. Combe C, Beck W, Argiles A, Brunet P, Chauveau P, Choukroun G, et al. Influence of hemodialysis (HD) membrane (Mb) permeability (Perm) in patients (Pts) with mild chronic inflammation: results from INFLUX, a randomized controlled multicenter clinical trial [abstract]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):485A.
45. Combe C, Beck W, Argiles A, Brunet P, Chauveau P, Choukroun G, et al. Influence of hemodialysis (HD) membrane permeability (perm) in patients (Pts) with mild chronic inflammation: Intermediate results from INFLUX, a randomized controlled multicenter study [abstract]. Journal of the American Society of Nephrology 2007;18(Abstracts):517A.
46. Jeloka T, Mathur MD, Kaur R, Kohli R, Singh NP, Rizvi SNA. I2 microglobulin in chronic renal failure and effect off different dialyzer membrane on its clearance. Indian Journal of Nephrology 2001;11(4):160-4. [CENTRAL: CN-00663574]
47. Klemm A, Franke C, Busch M, Muller A, Franke S, Lang D, Passlick-Deetjen J, Stein G. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites. Clinical Nephrology 2004;61(3):191-7. [MEDLINE: 15077870]
48. Krieter DH, Sauer N, Reinhardt B, Lemke HD, Foitzik-Kisseler M, Hartwig M, et al. No evidence for pyrogen transfer in haemodialysis (hd) with low-and high-flux dialyzers [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):21.
49. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. American Journal of Nephrology 1996;16(6):484-8. [MEDLINE: 8955759]
50. Kuchle C, Fricke H, et al. High-flux hemodialysis postpones clinical manifestation of dialysis associated amyloidosis [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A232. [CENTRAL: CN-00261301]
51. Kuchle C, Lang SM, Held E, Schiffl H. Biocompatibility, b2-microglobulin and dialysis-associated amyloidosis [abstract]. Nephrology 1997;3(Suppl 1):S404.
52. Mrowka CH, Schiffl H. Comparative evaluation of beta-2 microglobulin removal by different hemodialysis membranes: a six year follow-up. Nephron 1993;63(3):368-9. [MEDLINE: 8446285]
53. Schiffl H, D'Agostini B, Held E. Removal of beta 2-microglobulin by hemodialysis and hemofiltration: a four year follow up. Biomaterials, Artificial Cells, & Immobilization Biotechnology 1992;20(5):1223-32. [MEDLINE: 1457695]
54. Schiffl H, Kuchle C, Held E. Beta-2-microglobulin removal by different hemodialysis membranes. Contributions to Nephrology 1995;112:156-63. [MEDLINE: 7554987]
55. Lang SM, Bergner A, Topfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Peritoneal Dialysis International 2001;21(1):52-7. [MEDLINE: 11280496]
56. Li M, Jiang GR. High- versus low-flux hemodialysis in removing solutes. Journal of Clinical Rehabilitative Tissue Engineering Research 2007;11(31):6207-10. [EMBASE: 2007458081]
57. Li PK, Cheng YL, Leung CB, Szeto CC, Chow KM, Kwan BC, et al. Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial. Clinical Journal of the American Society of Nephrology 2010;5(4):652-8. [MEDLINE: 20203165]
58. Li PKT, Cheng YL, Leung CB, Szeto CC, Chow KM, Kwan BCH, et al. A randomized cross-over trial comparing low-flux polyamide membrane to high-flux polyamide membrane on inflammatory indices and arterial stiffness [abstract]. Journal of the American Society of Nephrology 2007;18(Abstracts):452A.
59. Locatelli F, Italian Cooperative Dialysis Study Group. Effect of hemodialysis membranes on serum albumin. American Journal of Kidney Diseases 2001;37(2):455-6. [MEDLINE: 11157397]
60. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney International 1996;50(4):1293-302. [MEDLINE: 8887291]
61. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, et al. The effects of different membranes and dialysis technologies on the treatment tolerance and nutritional parameters of hemodialysis patients [abstract]. Journal of the American Society of Nephrology 1996;7(9):1454.
62. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, Orlandini G. The effects of different membranes and dialysis technologies on the treatment tolerance and nutritional parameters of hemodialysed patients. Design of a prospective randomised multicentre trial. Journal of Nephrology 1994;7(2):123-9. [EMBASE: 1994156257]
63. Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrology Dialysis Transplantation 2000;15(9):1399-409. [MEDLINE: 10978398]
64. Mohini R, Michaels R, Trost C, Gron D, Zasuwa G, Dumler F, et al. Comparison of effect of recombinant human erythropoietin (rHEPO) in patients on high flux (HF) vs conventional (C) hemodialysis [abstract]. Kidney International 1989;35(1):256.
65. Hannedouche T, Jacobson SH, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, et al. Relationship of residual renal function (RRF) to serum b2-microglobulin and advanced glycation end products in patients starting hemodialysis (HD) [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):356A. [CENTRAL: CN-00445636]
66. Jacobson SH, Czekalski S, Hannedouche T, Loureiro A, Martin-Malo A, Papadimitriou M, et al. Modifiable cardiovascular risk factors: baseline results of the MPO study [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):614A.
67. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. Journal of Nephrology 1999 Mar;12(2):85-8. [MEDLINE: 10378663]
68. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Effect of Membrane Permeability on Survival of Hemodialysis Patients. Journal of the American Society of Nephrology 2009;20(3):645-54. [MEDLINE: 19092122]
69. Locatelli F, Pozzoni P, Di Filippo S. What are we expecting to learn from the MPO study?. Contributions to Nephrology 2005;149:83-9. [MEDLINE: 15876831]
70. Martin-Malo A, Czekalski S, Hannedouche T, Jacobson SH, Loureiro A, Papadimitriou M, et al. Patient and treatment patterns at start of dialysis: analysis of the effect of age [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):196-7.
71. Vanholder R, Hannedouche T, Jacobson SH, La Greca G, Loureiro A, Martin-Malo A, et al. Male gender as risk factor to be underdialysed: baseline data from the MPO study [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):250.
72. Vanholder R, Hannedouche T, Jacobson SH, Ronco C, Loureiro A, Martin-Malo A, et al. Protein catabolic rate (PCR) normalised to ideal body weight (BW) as indicator of protein intake: data from the MPO study [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):389A-90A.
73. Opatrny K Jr, Reischig T, Eiselt J, Vienken J, Opatrna S, Sefrna F, et al. Does treatment with biocompatible 'high-flux' (HF) and 'low-flux' (LF) hemodialysis (HD) differ in it's effect on renal anemia? [abstract]. Kidney & Blood Pressure Research 2001;24(2):131. [CENTRAL: CN-00509397]
74. Opatrny K, Reischig T, Vienken J, Eiselt J, Vit L, Opatrna S, et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artificial Organs 2002;26(2):181-8. [MEDLINE: 11879248]
75. Ottosson P, Attman PO, Knight C, Samuelsson O, Weiss L, Alaupovic P. Do high-flux dialysis membranes affect renal dyslipidemia?. ASAIO Journal 2001;47(3):229-34. [MEDLINE: 11374763]
76. Rizvi SNA, Sawlani KK, Kohli R. Comparative study of high flux haemodialysis versus conventional haemodialysis: Initial Indian experience [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:100.
77. Sawaya B, Provenzano R, Simkins R, Barkley G, Levin NW. Long term effect of conventional and high flux membranes on electrophysiologic (EP) indices in hemodialysis patients. Kidney International 1989;35(1):262.
78. Simon P, Ang KS, Cam G, Benziane A, Bonn F. Indices of adequate dialysis in patients hemodialyzed with AN 69 membrane. Kidney International 1993;43(Suppl 41):S291-5. [MEDLINE: 8320940]
79. Skroeder NR, Jacobson SH, Holmquist B, Kjellstrand P, Kjellstrand CM. Beta 2-microglobulin generation and removal in long slow and short fast hemodialysis. American Journal of Kidney Diseases 1993;21(5):519-26. [MEDLINE: 8488820]
80. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artificial Organs 1994;18(12):880-7. [MEDLINE: 7887824]
81. Takasawa K, Takaeda C, Nakagen M, Kawai K, Nakaya I, Kitagawa K, et al. Effect of high-flux dialysis on the anemia-prospective randomized crossover study [abstract]. Nephrology 2005;10(Suppl):A184.
82. Abe M, Kikuchi F, Kaizu K, Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clinical Nephrology 2008;69(5):354-60. [MEDLINE: 18538098]
83. Abe M, Okada K, Maruyama T, Ikeda K, Kikuchi F, Kaizu K, et al. Comparison of the effects of polysulfone and polyester-polymer alloy dialyzers on glycemic control in diabetic patients undergoing hemodialysis. Clinical Nephrology 2009; Vol. 71, issue 5:514-20. [MEDLINE: 19473611]
84. Alarcon A, Almaraz M, Alvarez Lipe R, Andres E, Arias M, Belvis JJ, et al. A multicentric study on the effectiveness of the cellulose triacetate membrane in haemodialysis patient. Nefrologia 1994;14(2):195-206. [EMBASE: 1994188445]
85. Albertazzi MM, Bonomini M. Clinical experience with PMMA membrane. Contributions to Nephrology 1999;125:213-221. [MEDLINE: 9895442]
86. Amadori A, Candi P, Sasdelli M, Massai G, Favilla S, Passaleva A, et al. Hemodialysis leukopenia and complement function with different dialyzers. Kidney International 1983;24(6):775-81. [MEDLINE: 6562280]
87. Andreoli MC, Dalboni MA, Watanabe R, Manfredi SR, Canziani ME, Kallas EG, et al. Impact of dialyzer membrane on apoptosis and function of polymorphonuclear cells and cytokine synthesis by peripheral blood mononuclear cells in hemodialysis patients. Artificial Organs 2007;31(12):887-92. [MEDLINE: 17924987]
88. Andreoli MCC, Dalboni MA, Watanabe R, Sardenberg C, Manfredi SR, Canziani ME, et al. A crossover study on the impact of dialyzer membrane selection on apoptosis and function of neutrophils and PBMC in hemodialysis patients [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):367A.
89. Arakawa M, Gejyo F, Shimotori T, Ei K, Oda M, Obata N, et al. Long-term multicentre study of beta2-microglobulin removal by PMMA BK membrane. Nephrology Dialysis Transplantation 1991;6(Suppl 2):69-74. [EMBASE: 1991241879]
90. Arnadottir M, Wingren K, Hultberg B, Hegbrant J. The postdialytic rise in the plasma total homocysteine concentration is delayed. Blood Purification 2002;20(4):334-7. [MEDLINE: 12169841]
91. Becker BN, Pintar TJ, Hofmann RM, Abdullah RN, Knechtle SJ, D'Alessandro AM. High-flux hemodialysis may improve delayed graft function [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):719A-20A.
92. Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Bergamo Collaborative Dialysis Study Group. Kidney International 1991;40(4):714-9. [MEDLINE: 1745022]
93. Bonomini V, Coli L, Feliciangeli G, Nanni Costa A, Scolari MP. Long-term comparative evaluation of synthetic and cellulosic membranes in dialysis. International Journal of Artificial Organs 1984;17(7):392-8. [EMBASE: 1994300741]
94. Bonomini M, Fiederling B, Bucciarelli T, Manfrini V, Di Ilio C, Albertazzi A. A new polymethylmethacrylate membrane for hemodialysis. International Journal of Artificial Organs 1996;19(4):232-9. [MEDLINE: 8786174]
95. Bonomini M, Fiederling B, Manfrini V, Martella D, Garofalo E, Bucciarelli T, et al. Evaluation of the removal capacity during hemodialysis (HD) of a novel polymethylmethacrylate (PMMA) membrane [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:563. [CENTRAL: CN-00509097]
96. Bordoni V, Piroddi M, Galli F, de Cal M, Bonello M, Dimitri P, et al. Oxidant and carbonyl stress-related apoptosis in end-stage kidney disease: impact of membrane flux. Blood Purification 2006;24(1):149-56. [MEDLINE: 16361856]
97. Bordoni VV, Brendolan AA, De Cal M, Levin NN, Crepaldi CC, Goepel WW, et al. Caspase 3-dependent apoptosis is corrected by high flux and middle flux but not by low flux membranes [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):405A.
98. Bosc JY, LeBlanc M, et al. Comparison between high flux cellulose triacetate and high flux polysulfone: a clinical study in hemodialysis and hemodiafiltration [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A150. [CENTRAL: CN-00261407]
99. Boudville N, Horner M, McEwan E, Lim WH, Mudge DW, Markus HE. Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients. Blood Purification 2009; Vol. 27, issue 2:187-93. [MEDLINE: 19141998]
100. Branger B, Deschodt G, Oules R, Balducchi JP, Granolleras C, Alsabadani B, et al. Biocompatible membranes and hemodynamic tolerance to hemodialysis. Kidney International - Supplement 1988;33(Suppl 24):196-7. [MEDLINE: 3163048]
101. Campbell J, Dumler F, Stalla K, Levin NW. High flux short time hemodialysis: initial clinical experience [abstract]. Kidney International 1987;31(1):229.
102. Caramelo C, Alcazar R, Gallar P, Teruel JL, Velo M, Ortega O, et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrology Dialysis Transplantation 1994;9(6):675-7. [MEDLINE: 7970095]
103. Schiffl H. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients [letter]. Nephrology Dialysis Transplantation 1995;10(6):911-2. [MEDLINE: 7566634]
104. Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, et al. Platelet activation on hemodialysis: influence of dialysis membrane. Kidney International - Supplement 1993;41:S217-20. [MEDLINE: 8320925]
105. Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F. Carpal tunnel syndrome and type of dialysis membrane. BMJ 1989;298(6677):867-8. [MEDLINE: 2497828]
106. Chauveau P, Poignet JL, Kuno T, Bonete R, Kerembrun A, Naret C, et al. Phosphate removal rate: a comparative study of five high-flux dialysers. Nephrology Dialysis Transplantation 1992;6(Suppl 2):114-5. [MEDLINE: 1866059]
107. Chen X, Li Z, Wu P, Zhang D, Shen Q, Yu X. b2-microglobulin and iPTH removal in on-line hemodiafiltration versus low- and high-flux hemodialysis [abstract]. Nephrology 2005;10(Suppl):A185.
108. Churchill DN. Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: An appraisal of the evidence. Nephrology Dialysis Transplantation 1995;10 Suppl 10:52-6. [MEDLINE: 8825434]
109. Civati G, Teatini U, Guastoni C, Perego A, Perrino ML, Ballerini L, et al. Long-term experience with high-flux polysulfone in hemodialysis. Clinical Nephrology 1994;42 Suppl 1:S26-30. [MEDLINE: 7923979]
110. Combe C, Pourtein M, de Precigout V, Baquey A, Morel D, Potaux L, et al. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. American Journal of Kidney Diseases 1994;24(3):437-42. [MEDLINE: 8079969]
111. Gritters-van den Oever M, Grooteman MP, Bartels PC, Blankestijn PJ, Bots ML, van den Dorpel MA, et al. Post-dilution haemodiafiltration and low-flux haemodialysis have dissimilar effects on platelets: a side study of CONTRAST. Nephrology Dialysis Transplantation 2009; Vol. 24, issue 11:3461-8. [MEDLINE: 19561150]
112. Penne EJ, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al. [New study evaluating online haemodiafiltration for the reduction of cardiovascular morbidity and mortality in patients undergoing chronic haemodialysis]. [Dutch]. Nederlands Tijdschrift voor Geneeskunde 2006;150(28):1583-5. [MEDLINE: 16886698]
113. Penne EL, Blankestijn PJ, Bots ML, Ban Den Dorpel MA, Grooteman MP, Nube MJ, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients: design and rationale of the Dutch CONvective TRAnsport STudy (CONTRAST) [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):406A.
114. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Current Controlled Trials in Cardiovascular Medicine 2005;6(1):8. [MEDLINE: 15907201]
115. Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Seminars in Dialysis 2005 Jan;18(1):47-51. [MEDLINE: 15663765]
116. Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, et al. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). American Journal of Kidney Diseases 2010; Vol. 55, issue 1:77-87. [MEDLINE: 19962805]
117. Penne L, Blankestijn P, Bots M, Van den Dorpel MA, Grooteman M, Nube M, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic dialysis patients: design and preliminary baseline characteristics of the CONvective TRAnsport STudy (CONTRAST) [abstract]. Nephrology 2005;10(Suppl):A189.
118. Penne L, Blankestijn P, Bots M, Van den Dorpel R, Grooteman M, Nube M, et al. The CONvective TRAnsport STudy (CONTRAST) is designed to detect differences in mortality and cardiovascular disease between online hemodiafiltration and hemodialysis: preliminary findings on proof of principle [abstract]. Journal of the American Society of Nephrology 2005;16:734A.
119. van der Weerd N, Blankestijn P, Bots M, Van den Dorpel R, Grooteman M, Nube M, et al. Dose dependent decrease in beta-2-microglobulin (b2M) levels in patients treated with online hemodiafiltration (HDF) in the Dutch CONvective TRAnsport STudy (CONTRAST) [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):53A.
120. Danielson BG, Hallgren R, Venge P. Patient reactions and granulocyte degranulation during hemodialysis with cuprophane and polycarbonate membranes. A double-blind study. Blood Purification 1986;4(1-3):147-50. [MEDLINE: 3524607]
121. Daugirdas JT. The possible effects of dialyzer membrane on morbidity and mortality. Nephrology Dialysis Transplantation 1994;9 Suppl 2:145-9. [MEDLINE: 8065606]
122. De Francisco AL, Amado JA, Prieto M, Sanz de Castro S, Ruiz JC, Morales P, et al. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism. Nephron 1994;66(4):442-6. [MEDLINE: 8015649]
123. Dellanna F, Lagendijk H, Westhoff A, Kleophas W, van Endert G. Superflux-dialyser and the genius system: the effect of internal filtration on beta-2-microglobulin elimination [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A213.
124. Demirtas S, Nergisoglu G, Akbay A, Karaca L. The relation between low-density lipoprotein (LDL) oxidation and hemodialysis with respect to membrane types: Protective effects of vitamin E-bonded membrane. Turkish Journal of Medical Sciences 2002;32(2):93-100. [EMBASE: 2002122144]
125. De Precigout V, Higueret D, Larroumet N, Combe C, Iron A, Blanchetier V, et al. Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis. Blood Purification 1996;14(2):170-6. [MEDLINE: 8785033]
126. Descamps-Latscha B, Goldfarb B, Nguyen AT, Landais P, London G, Haeffner-Cavaillon N, et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study. Nephron 1991;59(2):279-85. [MEDLINE: 1956490]
127. Dhakal MP, Kallay MC, Shelly MA, Talley TE. Post-hemodialysis hypoxia occurs with both biocompatible and bioincompatible dialyzers. Dialysis & Transplantation 1999;28(11):666-72. [EMBASE: 1999388080]
128. Ding F, Lin S, Fan S. The clinical effect of high-flux dialysis and it's influence on plasma cytokine level [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:291.
129. Diop ME, Viron B, Bailleul S, Lefevre G, Fessi H, Maury J, et al. Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane: A 2-year follow-up study. Clinical Nephrology 2000;54(3):210-7. [MEDLINE: 11020019]
130. Docci D, Bilancioni R, Pistocchi E, Baldrati L, Capponcini C, Delvecchio C, et al. Evolution of serum prealbumin following hemodialysis: effect of different dialysis membranes. Nephron 1992;62(2):145-9. [MEDLINE: 1436305]
131. Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C. Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 1995;69(3):323-6. [MEDLINE: 7753268]
132. Domrongkitchaiporn S, Chuncharunee S, Archararit N, Atamasirikul K, Vanichakarn S. Effect of dialyzer membranes on beta-2 microglobulin production in Thai hemodialysis patients. Journal of the Medical Association of Thailand 1997;80 Suppl 1:S138-43. [MEDLINE: 9347661]
133. Donovan KL, Pacholok S, Phillips A, Humes JL, Coles GA, Williams JD. Effect of dialyser composition and reuse on neutrophil count and elastase alpha-1 proteinase inhibitor complex formation. International Journal of Artificial Organs 1992;15(3):139-43. [MEDLINE: 1521897]
134. Falkenhagen D, Bosch T, Brown GS, Schmidt B, Holtz M, Baurmeister U, et al. A clinical study on different cellulosic dialysis membranes. Nephrology Dialysis Transplantation 1987;2(6):537-45. [MEDLINE: 3126455]
135. Ferreira A, Urena P, Ang KS, Simon P, Morieux C, Souberbielle JC, et al. Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients. Nephrology Dialysis Transplantation 1995;10(9):1701-7. [MEDLINE: 8559492]
136. Fourtounas C, Kopelias I, Dimitriadis G, Agroyannis B, Locatelli F, Andrulli S. The impact of dialyzers on the anaemia of haemodialysis patients. Nephrology Dialysis Transplantation 2001;16(5):1077-8. [MEDLINE: 11328925]
137. Fox SD, Henderson LW. Cardiovascular response during hemodialysis and hemofiltration: thermal, membrane, and catecholamine influences. Blood Purification 1993;11(4):224-36. [MEDLINE: 8297564]
138. Franke S, Klemm A, Franke C, Niwa T, Lang D, Passlick-Deetjin J, et al. The impact of a new high-flux membrane -helixone- on serum age levels [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):717A.
139. Gascon A, Lerma JL, Orfao A, Lopez Fernandez A, Ciudad J, Tabemero JM. Behaviour of natural killer cells and TCR g-d lymphocytes during hemodialysis with different membranes [abstract]. 12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel. 1993:319.
140. Girndt M, Heisel O, Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrology Dialysis Transplantation 1999;14(23):676-82. [MEDLINE: 10193818]
141. Gonella M, Mazzotta A, Calabrese G, Guaschino R, Vagelli G, Pratesi G. Comparison between heparin dose during hemodiafiltration with high flux synthetic membranes. International Journal of Artificial Organs 1994;17(1):61-2. [MEDLINE: 8188402]
142. Grekas D, Syrganis C, Georgiou T, Zegla O, Tourkantonis A. Biocompatibility of cuprophan and cellulose acetate membranes. Prevention of dialysis hypoxemia and leucopenia by ticlopidine. Life Support Systems 1985;3 Suppl 1:68-72. [MEDLINE: 3870624]
143. Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon. ASAIO Journal 1995;41(2):215-20. [MEDLINE: 7640431]
144. Grooteman M, Nube M, van Houte A, Schoorl M, van Geelen J. Dialyser membrane elution yields pmn with degranulative activity and little adherence [abstract]. Journal of the American Society of Nephrology 1994;5(3):450.
145. Grooteman M, Nube M, van Houte A, Schoorl M, van Geelen J. Lymphocyte subsets in dialyser eluates might represent an index of biocompatibility [abstract]. Journal of the American Society of Nephrology 1994;5(3):450.
146. Grooteman MP, Nube MJ, et al. Evidence of marked degranulative activity in polymorphonuclear cells (PMN) from dialyzer eluates [abstract]. Nephrology Dialysis Transplantation 1995;10(6):1034.
147. Grooteman MP, Nube MJ, et al. Lymphocyte subsets in dialyzer eluates represent an index of bio-incompatibility [abstract]. Nephrology Dialysis Transplantation 1995;10(6):1034.
148. Grooteman MP, Nube MJ, van Houte AJ, Schoorl M, van Limbeek J. Granulocyte sequestration in dialysers: a comparative elution study of three different membranes. Nephrology Dialysis Transplantation 1995;10(10):1859-64. [MEDLINE: 8592594]
149. Grooteman MP, Nube MJ, van Limbeek J, Schoorl M, van Houte AJ. Lymphocyte subsets in dialyser eluates: a new parameter of bioincompatibility. Nephrology Dialysis Transplantation 1996;11(6):1073-8. [MEDLINE: 8671971]
150. Grooteman MP, Nube MJ, Daha MR, Van Limbeek J, van Deuren M, Schoorl M, et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. Journal of the Amercian Society of Nephrology 1997;8(11):1745-54. [MEDLINE: 9355078]
151. Grooteman MP, Gritters M, Wauters IM, Schalkwijk CG, Stam F, Twisk J, et al. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients. Nephrology Dialysis Transplantation 2005;20(12):2751-8. [MEDLINE: 16188898]
152. Grooteman MP, Wauters IM, Teerlink T, Twisk JW, Nube MJ. Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purification 2007;25(3):281-9. [MEDLINE: 17622710]
153. Haag-Weber M, Mai B, Deppisch R, Gohl H, Horl WH. Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate. Clinical Nephrology 1994;41(4):245-51. [MEDLINE: 8026120]
154. Hakim RM. Recent advances in the biocompatibility of haemodialysis membranes. Nephrology Dialysis Transplantation 1995;10 Suppl 10:7-11. [MEDLINE: 8825426]
155. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. Journal of the American Society of Nephrology 1996;7(3):472-8. [MEDLINE: 8704114]
156. Hakim RM, Wingard RL, Ikizler TA, Parker RA, Vanholder R, Husni L, et al. Effects of biocompatibility on nutritional status in chronic hemodialysis patients (chd) [abstract]. Journal of the American Society of Nephrology 1994;5(3):451.
157. Hakim RM, Wingard RL, Parker RA, Vanholder R, Husni L, Parker TF 3rd. Effects of biocompatibility on hospitalizations and infectious morbidity in chronic hemodialysis patients (CHD) [abstract]. Journal of the American Society of Nephrology 1994;5(3):450.
158. Haque SS, Ishaque M, Rashid HU, Rahman D. Study of effectivity and patient well being with cupraphan and cellulose acetate membrane dialyzer. Bangladesh Renal Journal 1994;13(1):24-7. [EMBASE: 1994252457]
159. Hardouin P, Flipo RM, Foissac-Gegoux P, Dumont A, Duquesnoy B, Delcambre B. Dialysis-related beta 2 microglobulin-amyloid arthropathy. Improvement of clinical symptoms after a switch of dialysis membranes. Clinical Rheumatology 1988;7(1):41-5. [MEDLINE: 3044672]
160. Haufe CC, Eismann U, Deppisch R, Stein G. Is the expression of beta-2-microglobulin messenger-RNA influenced by high-flux or low-flux dialyzer membranes? [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):282A.
161. Haufe CC, Eismann U, Deppisch R, Stein G. MRNA expression of beta-2-microglobulin (b2-m) and c-fos in patients with chronic renal replacement therapy [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):563A.
162. Haufe CC, Eismann U, Deppisch RM, Stein G. Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes?. Kidney International - Supplement 2001;78:S177-81. [MEDLINE: 11169006]
163. Heisel O, Girndt M, Kohler H. Does a high flux membrane influence the monokine production of chronic dialysis patients? [abstract]. Journal of the American Society of Nephrology 1995;6(3):533.
164. Heisel O, Girndt M, Kohler H. Influence of a high flux membrane on the cytokine production of chronic dialysis patients [abstract]. Nephrology Dialysis Transplantation 1996;11(7):1472. [CENTRAL: CN-00261184]
165. Hernandez MR, Palomo M, Fuste B, Carbo C, Collado S, Cases A, et al. Effect of two different dialysis membranes on leukocyte adhesion and aggregation. Nephron 2007;106(1):c1-8. [MEDLINE: 17347577]
166. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. Journal of the American Society of Nephrology 1993;4(2):178-86. [MEDLINE: 8400081]
167. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney International 1996;50(2):566-70. [MEDLINE: 8840287]
168. Hakim RM, Tolkoff-Rubin N, Himmelfarb J, Wingard RL, Parker RA. A multicenter comparison of bioincompatible (bicm) and biocompatible (bcm) membranes in the treatment of acute renal failure (arf) [abstract]. Journal of the American Society of Nephrology 1994;5(3):394.
169. Hakim RM, Wingard RL, Lawrence P, Parker RA, Schulman G. Use of biocompatible membranes (bcm) improves outcome and recovery from acute renal failure (arf) [abstract]. Journal of the American Society of Nephrology 1992;3(3):367.
170. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure.[see comment]. New England Journal of Medicine 1994;331(20):1338-42. [MEDLINE: 7935703]
171. Himmelfarb J, Tolkoff RN, Chandran P, Parker RA, Wingard RL, Hakim R. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. Journal of the American Society of Nephrology 1998;9(2):257-66. [MEDLINE: 9527402]
172. Parker RA, Himmelfarb J, Tolkoff-Rubin N, Chandran P, Wingard RL, Hakim RM. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study. American Journal of Kidney Diseases 1998;32(3):432-43. [MEDLINE: 9740160]
173. Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J. Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrology Dialysis Transplantation 1994;9(1):60-6. [MEDLINE: 8177478]
174. Hoenich NA, Woffindin C, Mathews JN, Vienken J. Biocompatibility of membranes used in the treatment of renal failure. Biomaterials 1995;16(8):587-92. [MEDLINE: 7548608]
175. Hoenich NA, Woffindin C, Cox PJ, Goldfinch M, Roberts SJ. Clinical characterization of Dicea a new cellulose membrane for haemodialysis. Clinical Nephrology 1997;48(4):253-9. [MEDLINE: 9352161]
176. Hoenich NA, Stamp S. Clinical performance of a new high-flux synthetic membrane. American Journal of Kidney Diseases 2000;36(2):345-52. [MEDLINE: 10922313]
177. Hoenich NA, Stamp S, Roberts SJ. A microdomain-structured synthetic high-flux hollow-fiber membrane for renal replacement therapy. ASAIO Journal 2000;46(1):70-5.
178. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. Journal of the Amercian Society of Nephrology 1992;3(6):1227-37. [MEDLINE: 1477318]
179. Hornych A, Remy P, Loung N, Aumont J, Bariety J. Biocompatibility of haemodialysis membranes: haemodialysis-related leukotriene B4 and C4 generation. Nephron 1996;74(1):11-8. [MEDLINE: 8883014]
180. Huraib S, Tanimu D, Shaheen F, Hejaili FM, Giles C, Pagayon V. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study. American Journal of Nephrology 2000;20(5):364-8. [MEDLINE: 11092992]
181. Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins--a cross-over trial. Nephrology Dialysis Transplantation 1998;13(6):1452-7. [MEDLINE: 9641175]
182. Iorio L, Saltarelli G, Nacca RG, Simonelli R, Violi F. Hyperlipidemia in dialysis patients: What treatment?. Mineral and Electrolyte Metabolism 1997;23(3-6):311-3. [MEDLINE: 9387140]
183. Ivanovich P, Chenoweth DE, Schmidt R, KlinkmannH, Boxer L A, Jacob HS, et al. Symptoms and activation of granulocytes and complement with two dialysis membranes. Kidney International 1983;24(6):758-63. [MEDLINE: 6609268]
184. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. American Journal of Kidney Diseases 1992;20(4):361-6. [MEDLINE: 1415204]
185. Kasama R, Koch T, Canals-Navas C, Pitone JM. Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature. American Journal of Kidney Diseases 1996;27(5):680-6. [MEDLINE: 8629628]
186. Kato A, Takita T, Furuhashi M, Takahashi T, Watanabe T, Maruyama Y, et al. Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha. Artificial Organs 2001;25(6):441-7. [MEDLINE: 11453873]
187. Kim S, Oh KH, Chin HJ, Na KY, Kim YS, Chae DW, et al. Effective removal of leptin via hemodiafiltration with on-line endogenous reinfusion therapy. Clinical Nephrology 2009; Vol. 72, issue 6:442-8. [MEDLINE: 19954721]
188. Kino K, Akizawa T, Koshikawa S. Effects of membrane characteristics on cytokine production by mononuclear cells in regular haemodialysis patients. Nephrology Dialysis Transplantation 1995;10 Suppl 3:29-33. [MEDLINE: 7494611]
189. Kirschbaum B. The decline in serum albumin after conversion to high flux, high efficiency dialysis. Artificial Organs 1994;18(10):729-35. [MEDLINE: 7832653]
190. Klemm A, Sperschneider H, Winnefeld K, Gunther K, Stein G. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients. Clinical Nephrology 1997;47(2):133-4. [MEDLINE: 9049466]
191. Klinkmann H, Buscaroli A, Stefoni S. Beta2-microglobulin and low-flux synthetic dialyzers. Artificial Organs 1998;22(7):585-90. [MEDLINE: 9684696]
192. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney International 1997;52(4):1096-101. [MEDLINE: 9328951]
193. Kramer BK, Pickert A, Hohmann C, Liebich HM, Muller GA, Hablitzel M, et al. In vivo clearance and elimination of nine marker substances during hemofiltration with different membranes. International Journal of Artificial Organs 1992;15(7):408-12. [MEDLINE: 1516991]
194. Krieter DH, Lemke HD, Wanner C. A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal. Artificial Organs 2008;32(7):547-54. [MEDLINE: 18638309]
195. Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrology Dialysis Transplantation 2010; Vol. 25, issue 1:212-8. [MEDLINE: 19755476]
196. Lee D, Haase M, Haase-Fielitz A, Paizis K, Goehl H, Bellomo R. A pilot, randomized, double-blind, cross-over study of high cut-off versus high-flux dialysis membranes. Blood Purification 2009; Vol. 28, issue 4:365-72. [MEDLINE: 19729908]
197. Leitienne P, Trzeciak MC, Adeleine P, Ville D, Dechavanne M, Traeger J, et al. Comparison of hemostasis with two high-flux hemocompatible dialysis membranes. International Journal of Artificial Organs 1991;14(4):227-33. [MEDLINE: 1829439]
198. Levin N, Zasuwa G, Klinkmann H. Introduction, demography, and general methods. Nephrology Dialysis Transplantation 1993;8(Suppl 2):2-7. [MEDLINE: 8272247]
199. Levin NW, Zasuwa G. Relationship between dialyser type and signs and symptoms. Nephrology Dialysis Transplantation 1993;8(Suppl 2):30-9. [MEDLINE: 8272250]
200. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, et al. Cytokine production during hemodialysis: Effects of dialytic membrane and complement activation. American Journal of Nephrology 1996;16(4):293-9. [MEDLINE: 8739281]
201. Linnenweber S, Lonnemann G. Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells. Kidney International - Supplement 2001;78:S282-5. [MEDLINE: 11169027]
202. Locatelli F. Influence of membranes on morbidity. Nephrology Dialysis Transplantation 1996;11(Suppl 2):116-20. [MEDLINE: 8804010]
203. Locatelli F, Di Filippo S, Manzoni C. The effect of dialysis membrane on serum beta2-microglobulin in chronic haemodialysis patients. Nephrology Dialysis Transplantation 1997;12(12):2804. [EMBASE: 1997378135]
204. Locatelli F, Andrulli S, Del Vecchio L. Anemia of hemodialysis patients: evaluation of the effect of BK-F polymethylmethacrylate membrane. Contributions to Nephrology 1999;125:173-81. [MEDLINE: 9895439]
205. Locatelli F, Di Filippo S, Manzoni C. Removal of small and middle molecules by convective techniques. Nephrology Dialysis Transplantation 2000;15 Suppl 2:37-44. [MEDLINE: 11051036]
206. Locatelli F, Andrulli S, D'Amico M. Evaluation of dialysis outcomes: experimental versus observational evidence. Journal of Nephrology 2001;14 Suppl 4:S101-8. [MEDLINE: 11798140]
207. Locatelli F, Del Vecchio L, Andrulli S. Dialysis: its role in optimizing recombinant erythropoietin treatment. Nephrology Dialysis Transplantation 2001;16 Suppl 7:29-35. [MEDLINE: 11590254]
208. Locatelli F. Optimizing dose and mode of renal replacement therapy in anaemia management. Nephrology Dialysis Transplantation 2002;17 Suppl 5:60-5. [MEDLINE: 12091610]
209. Loocatelli F. Dose of dialysis, convection and haemodialysis patients outcome - What the HEMO study doesn't tell us: The European viewpoint. Nephrology Dialysis Transplantation 2003;18(6):1061-5. [MEDLINE: 12748335]
210. Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello C. A switch to high-flux Helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis. Blood Purification 2003;21(3):225-31. [MEDLINE: 12784048]
211. Lundberg L, Stegmayr BG, Wehle B. Backdiffusion or bicarbonate may stimulate complement activation during haemodialysis with low-flux membranes. International Journal of Artificial Organs 1994;17(3):131-6. [MEDLINE: 8050803]
212. MacGinley R, Westhuyzen J, Saltissi D, Morgan C, Healy H, Thirlwell GK, et al. Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer. ASAIO Journal 2001;47(1):66-73. [MEDLINE: 11199319]
213. Maheut H, Lacour F. Using AN69 ST membrane: a dialysis centre experience. Nephrology Dialysis Transplantation 2001;16(7):1519-20. [MEDLINE: 11427664]
214. Santoro A, Mancini E, Bolzani R, Boggi R, Cagnoli L, Francioso A, et al. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. [see comment]. American Journal of Kidney Diseases 2008;52(3):507-18. [MEDLINE: 18617304]
215. Santoro A, Mancini E, MAMHEBI Study Group. Effects of online hemofiltration (OL-HF) versus bicarbonate dialysis (BD) on mortality and morbidity in hemodialysis (HD) patients: a prospective, randomized, multicenter trial (MAMHEBI Study) [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):24A.
216. Mandolfo S, Borlandelli S, Imbasciati E, Badalamenti S, Graziani G, Sereni L, et al. Pilot study to assess increased dialysis efficiency in patients with limited blood flow rates due to vascular access problems. Hemodialysis International 2008;12(1):55-61. [MEDLINE: 18271842]
217. Mann H, Al-Bashir A, Melzer H, Stiller S. Diacap alpha-polysulfone HI PS: a new dialysis membrane with optimum beta2-microglobulin elimination. International Journal of Artifical Organs 2003;26(6):461-6. [MEDLINE: 12866651]
218. Martinez Ara J, Sanz Moreno C, Perez Garcia R. Cooperative study of nutrition in hemodialysis IV. Hemodialysis techniques and nutritional parameters. Nefrologia 1994;14(Suppl 2):51-9. [EMBASE: 1994230874]
219. Martin-Malo A, Castillo D, Castro M, Perez R, Rios A, Jaraba M, et al. Biocompatibility of dialysis membranes: a comparative study. Nephrology Dialysis Transplantation 1991;6 Suppl 2:55-8. [MEDLINE: 1866069]
220. Martin-Malo A, Castillo D, Castro M, Perez R, Rios A, Jaraba M, et al. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon. Kidney International - Supplement 1993;41:S213-6. [MEDLINE: 8320924]
221. Martos MR, Hendry BM, Rodriguez-Puyol M, Dwight J, Diez-Marques ML, Rodriguez-Puyol D. Haemodialyser biocompatibility and erythrocyte structure and function. Clinica Chimica Acta 1997;265(2):235-46. [MEDLINE: 9385465]
222. Matthews JN, Hoenich NA. Statistical aspects of the design and analysis of studies to compare haemodialysis membranes. Nephrology Dialysis Transplantation 1994;9 Suppl 2:176-83. [MEDLINE: 8065612]
223. Matzkies FK, Reinecke H, Tombach B, Kosch M, Hegger K, Milius M, et al. Influence of dialysis procedure, membrane surface and membrane material on iopromide elimination in patients with reduced kidney function. American Journal of Nephrology 2000;20(4):300-4. [MEDLINE: 10970983]
224. McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. American Journal of Kidney Diseases 1997;29(4):576-83. [MEDLINE: 9100048]
225. Mehrotra R, Bross R, Konishi T, Appel M, Tsoi L, Kopple JD. What is the optimal arterial pH for protein balance in automated peritoneal dialysis (APD) patients' [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):724A.
226. Mehrotra R, Bross R, Wang H, Appell M, Tso L, Kopple JD. Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. American Journal of Clinical Nutrition 2009; Vol. 90, issue 6:1532-40. [MEDLINE: 19846545]
227. Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, et al. Role of different dialysis membranes in the release of interleukin-6- soluble receptor in uremic patients. Kidney International 2000;58(1):417-24. [MEDLINE: 10886590]
228. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. American Journal of Kidney Diseases 2002;39(2):266-73. [MEDLINE: 11840366]
229. Memoli B, Bisesti V, Saravo MT, Esposito P, D'Arcangelo R, Nicosia V, et al. Cytokine production in standard hemodialysis with a new polyethersulfone membrane: a cross-over study. Contributions to Nephrology 2003;138:80-7. [MEDLINE: 12463149]
230. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C. Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality. International Journal of Artificial Organs 2002;25(11):1049-60. [MEDLINE: 12487392]
231. Mioli VA, Balestra E, Bibiano L, Dellabella S, Fanciulli E, Gaffi, G, et al. Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients. International Journal of Artificial Organs 1994;17(11):576-80. [MEDLINE: 7744516]
232. Mishkin MA, Mishkin GJ, Lew SQ. Solute removal in hemodiafiltration compared to standard high flux dialysis: combined analysis of 2 cross over studies [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):238a.
233. Moreno F, Lopez Gomez JM, Sanz-Guajardo D, Jofre R, Valderrabano F. Quality of life in dialysis patients. A spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrology Dialysis Transplantation 1996;11 Suppl 2:125-9. [MEDLINE: 8804012]
234. Moshfegh A, Jacobson SH, Hallden G, Thylen P, Lundahl J. Impact of hemodialysis membrane and permeability on neutrophil transmigration in vitro. Nephron 2002;91(4):659-65. [MEDLINE: 12138270]
235. Mudge D, Rogers R, Hollett P, Law B, Reiger K, Petrie JJP, et al. Plasma homocysteine levels with standard high flux haemodialysis compared with fx class dialysers [abstract]. Nephrology 2004;9(Suppl 1):A16.
236. Mudge DW, Rogers R, Hollett P, Law B, Reiger K, Petrie JJ, et al. Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrology Dialysis Transplantation 2005;20(10):2178-85. [MEDLINE: 16030045]
237. Muller TF, Seitz M, Eckle I, Lange H, Kolb G. Biocompatibility differences with respect to the dialyzer sterilization method. Nephron 1998;78(2):139-42. [MEDLINE: 9496728]
238. Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH. Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. American Journal of Kidney Diseases 2000;36(1):130-9. [MEDLINE: 10873882]
239. Navarro JF, Marcen R, Teruel JL, Martin del Rio R, Gamez C, Mora C, et al. Effect of different membranes on amino-acid losses during haemodialysis. Nephrology Dialysis Transplantation 1998;13(1):113-7. [MEDLINE: 9481725]
240. Navarro JF, Marcen R, et al. Effect of different membranes on amino-acid (AA) losses during haemodialysis (HD) [abstract]. Nephrology Dialysis Transplantation 1994;9:995.
241. Navarro JF, del Castillo N, Fernandez JL, Macia ML, Mendez ML, Chahin J, et al. Hemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations. Artificial Organs 1997;21(2):91-5. [MEDLINE: 9028489]
242. Nensel U, Rockel A, Hillenbrand T, Bartel J. Dialyzer permeability for low-molecular-weight proteins. Comparison between polysulfone, polyamide and cuprammonium rayon dialyzers. Blood Purification 1994;12(2):128-34. [MEDLINE: 7530014]
243. Ohi H, Tamano M, Sudo S. Cellulose membranes suppress complement activation in patients after hemodialysis. American Journal of Kidney Diseases 2001;38(2):384-9. [MEDLINE: 11479166]
244. Opatrny K Jr, Krouzecky A, Wirth J, Vit L, Eiselt J. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis. Artificial Organs 1998;22(10):816-20. [MEDLINE: 9790077]
245. Opatrny K, Sulkova S, Lopot F, Vit L, Valek A, Opatrny K. Clinical study of high-flux cuprammonium rayon hemodialysis membranes. Artificial Organs 1993;17(12):971-6. [MEDLINE: 8110071]
246. Opatrny K Jr, Vit L, Opatrna S, Polakovic V, Sefrna F, Sulkova S, et al. Hemocompatibility in hemodialysis and erythropoietin therapy. Artificial Organs 1995;19(8):814-20. [MEDLINE: 8573001]
247. Opatrny K, Krouzzecky A, Polanska K, Mares J, Tomsu M, Bowry SK, et al. Does an alteration of dialyzer design and geometry affect biocompatibility parameters?. Hemodialysis International 2006;10(2):201-8. [MEDLINE: 16623675]
248. Otti T, Khajehdehi P, Fawzy A, Gellens M, Bastani B. Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes. American Journal of Nephrology 2001;21(1):16-9. [MEDLINE: 11275627]
249. Ouseph R, Hutchison CA, Ward RA. Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers. [see comment]. Nephrology Dialysis Transplantation 2008;23(5):1704-12. [MEDLINE: 18156455]
250. Ward RA, Ouseph R, Utz J. Comparison of solute removal by high-flux dialyzers containing membranes of nominally similar synthetic polymers [abstract]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v118.
251. Panichi V, Bianchi AM, Cirami C, Parrini M, Andreini B, Finato V, et al. Paired filtration dialysis (PFD): Biocompatibility, dialytic efficiency and clinical tolerance in a long-term multicenter trial. Journal of Nephrology 1995;8(3):155-61. [EMBASE: 1995200632]
252. Parker TF 3rd, Wingard RL, Husni L, Alp Ikizler T, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney International 1996;49(2):551-6. [MEDLINE: 8821843]
253. Pellicano R, Polkinghorne K, Tuominen O, Woods F, Kerr P. Crossover trial of porous haemodialysis membrane compared to conventional high-flux membrane: assessment of middle molecule clearance and nutritional parameters [abstract]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi131.
254. Pellicano R, Polkinghorne K, Tuominen O, Woods F, Kerr PG. Improved clearance of beta 2-microglobulin with superflux dialysis membranes: a randomised double-blind crossover trial [abstract]. Journal of the American Society of Nephrology 2007;18(Abstracts):248A.
255. Pellicano R, Polkinghorne KR, Kerr PG. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial. American Journal of Kidney Diseases 2008;52(1):93-101. [MEDLINE: 18423807]
256. Pengloan J, Petit A, Thibaut G, Blanchier D, Bardos P. Biocompatibility of dialyser membranes: roles of membranes and of patients. Nephrology Dialysis Transplantation 1991;6 Suppl 2:59-60. [MEDLINE: 1866070]
257. Pereira BJ, Natov SN, Sundaram S, Schmid CH, Trabelsi FR, Strom JA, et al. Impact of single use versus reuse of cellulose dialyzers on clinical parameters and indices of biocompatibility. Journal of American Society of Nephrology 1996;7(6):861-70. [MEDLINE: 8793794]
258. Pickett TM, Cruickshank A, Greenwood RN, Taube D, Davenport A, Farrington K. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purification 2002;20(2):161-6. [MEDLINE: 11818679]
259. Buturovic J, Rus R, Ponikvar R, Kremzar B, Horvat M, Muzlovic I, et al. Low flux vs high flux synthetic membrane in the patients with acute renal failure and multiorgan failure treated with hemodialysis: prospective randomized study [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):128A.
260. Buturovic J, Rus R, Ponikvar R, Kremzar B, Horvat M, Muzlovic I, et al. Low flux vs. high flux synthetic membrane in the patients with acute renal failure and multiorgan failure treated with hemodialysis: Prospective randomized study [abstract]. International Journal of Artificial Organs 1998;21(10):625.
261. Ponikvar JB, Rus RR, Kenda RB, Bren AF, Ponikvar RR. Low-flux versus high-flux synthetic dialysis membrane in acute renal failure: prospective randomized study. Artificial Organs 2001;25(12):946-50. [MEDLINE: 11843761]
262. Quellhorst E. Hemofiltration - differential indication for hemodialysis with reference to hemodynamic and metabolic aspects [Hamofiltration-Differentialindikation zur hamodialyse unter berucksichtigung hamodynamischer und metabolischer aspekte]. Klinische Wochenschrift 1979;57(19):1061-8. [EMBASE: 1980037798]
263. Riegel W, Ulrich C, Sauernheimer S, Deppisch RM, Kohler H. Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response. Kidney International - Supplement 2001;78:S308-14. [MEDLINE: 11169032]
264. Risler T, Braun N, Hanel KD, Kuhlmann U, Skroch D, Muller GA. Do different dialysis-membranes affect beta 2-microglobulin kinetics during chronic hemodialysis?. International Journal of Artificial Organs 1994;17(11):581-4. [MEDLINE: 7744517]
265. Ritz E. Phosphate removal during dialysis - Does the membrane matter?. Clinical Nephrology 1994;42(Suppl 1):S57-60. [MEDLINE: 7923986]
266. Robles NR, Murga L, Galvan S, Esparrago JF, Sanchez-Casado E. Hemodialysis with cuprophane or polysulfone: Effects on uremic polyneuropathy. American Journal of Kidney Diseases 1993;21(3):282-7. [MEDLINE: 8383423]
267. Robles NR, Gomez-Ainsua C, Cruz A. Cellulose acetate and cuprophane for hemodialysis: Effects on protein catabolic rate. Nephron 1995;70(4):508-9. [MEDLINE: 7477664]
268. Ronco C, Fox K, Curtin C, Heifetz A. Evaluation of beta-2-microglobulin (b2m) removal by high flux dialysis [abstract]. Journal of the American Society of Nephrology 1995;6(3):500.
269. Sa HO, Freitas L, Alves V, Manuel R, Mario C. Annexin v-affinity assay to study lymphocyte apoptosis during low and high-flux hemodialysis [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 12):157.
270. Schaefer RM, Horl WH, Kokot K, Heidland A. Enhanced biocompatibility with a new cellulosic membrane: Cuprophan versus Hemophan. Blood Purification 1987;5(4):262-7. [MEDLINE: 3426830]
271. Schaefer RM, Fink E, Schaefer L, Barkhausen R, Kulzer P, Heidland A. Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers. American Journal of Nephrology 1993;13(6):473-7. [MEDLINE: 8141183]
272. Schaefer RM, Kulzer P, Gilge U, Schaefer L, Heidland A. Clinical evaluation of the new, steam-sterilized polysulfone high-flux dialyzer. Clinical Nephrology 1994;42 Suppl 1:S21-5. [MEDLINE: 7923978]
273. Schauer S, Stein G, Suss J, Falkenhagen D, Linss W. Phagocytosis activity of polymorphonuclear cells of normal persons and dialysis patients is influenced by different dialysis membranes. Nephrology Dialysis Transplantation 1991;6 Suppl 3:35-40. [MEDLINE: 1775265]
274. Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux. Nephrology Dialysis Transplantation 2000;15(6):840-5. [MEDLINE: 10831638]
275. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clinical Nephrology 2000;53(6):452-9. [MEDLINE: 10879665]
276. Schindler R, Boenisch O, Fischer HC, Eckardt KU, Frei U. Plasma c-reactive protein (CRP) and cytokine production in chronic dialysis patients is influenced by the dialysis membrane [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):225A.
277. Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clinical Nephrology 2003;59(6):447-54. [MEDLINE: 12834177]
278. Schonermarck U, Dengler C, Ebeling F, Heydenreich M, Hillebrand GF, Samtleben W. Comparative evaluation of oxidative and antioxidative capacity during high-flux hemodialysis using two different membranes. Clinical Nephrology 2006;66(5):357-63. [MEDLINE: 17140165]
279. Schonermarck U, Dengler C, Ebeling F, Heydenreich M, Hillebrand GF, Samtleben W. Comparative evaluation of oxidative and antioxidative capacity during high-flux hemodialysis using two different membranes. Nieren und Hochdruckkrankheiten 2007;36(4):128-35. [EMBASE: 2007253016]
280. Schouten WE, Grooternan MP, et al. Intermittent induction of the acute phase response by clinical hemodialysis: the influence of dialyzer membranes [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A175. [CENTRAL: CN-00261424]
281. Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrology Dialysis Transplantation 2000;15(3):379-84. [MEDLINE: 10692524]
282. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney International - Supplement 2001;78:S19-24. [MEDLINE: 11168977]
283. SchultzecG, Wagner K, Neumayer HH, Fitzner R, Molzahn M. Effect of dialyzer membranes on in vitro generation of eicosanoids. International Journal of Artificial Organs 1987;10(4):275-8. [MEDLINE: 3478308]
284. Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch KM, Floege J. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis?. Kidney International 1997;52(4):1077-83. [MEDLINE: 9328948]
285. Sethi D, Gower PE. Dialysis arthropathy, beta 2-microglobulin and the effect of dialyser membrane. Nephrology Dialysis Transplantation 1988;3(6):768-72. [MEDLINE: 3147418]
286. Sevillano G, Rodriguez-Puyol M, Martos R, Duque I, Lamas S, DiezMarques ML, et al. Cellulose acetate membrane improves some aspects of red blood cell function in haemodialysis patients. Nephrology Dialysis Transplantation 1990;5(7):497-9. [MEDLINE: 2130294]
287. Singh NP, Bansal R, Thakur A, Kohli R, Bansal RC, Agarwal SK. Effect of membrane composition on cytokine production and clinical symptoms during hemodialysis: a crossover study. Renal Failure 2003;25(3):419-30. [MEDLINE: 12803505]
288. Sirolli V, Ballone E, Amoroso L, Di Liberato L, Di Mascio R, Capelli P, et al. Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis: effects of different synthetic membranes. International Journal of Artificial Organs 1999;22(8):536-42. [MEDLINE: 10533909]
289. Sirolli V, Di Stante S, Stuard S, Di Liberato L, Amoroso L, Cappelli P, et al. Biocompatibility and functional performance of a polyethylene glycol acid-grafted cellulosic membrane for hemodialysis. International Journal of Artificial Organs 2000;23(6):356-64. [MEDLINE: 10919752]
290. Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane. International Journal Artificial Organs 2002;25(6):529-37. [MEDLINE: 12117292]
291. Sklar AH, Beezhoild DH, Newman N, Hendrickso T, Dreisbach AW. Postdialysis fatigue: Lack of effect of a biocompatible membrane. American Journal of Kidney Diseases 1998;31(6):1007-10. [MEDLINE: 9631846]
292. Sklar A, Newman N, Scott R, Semenyuk L, Schultz J, Fiacco V. Identification of factors responsible for postdialysis fatigue. American Journal of Kidney Diseases 1999;34(3):464-70. [MEDLINE: 10469856]
293. Skroeder NR, Jacobson SH, Lins L.E, Kjellstrand CM. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis. ASAIO Transactions 1990;36(3):M637-9. [MEDLINE: 2252771]
294. Sombolos K, Tsitamidou Z, Kyriazis G, Karagianni A, Kantaropoulou M, Progia E. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo. American Journal of Nephrology 1997;17(5):406-12. [MEDLINE: 9382156]
295. Sreeharan N, Crow MJ, Salter MC. Membrane effect on platelet function during hemodialysis: a comparison of cuprophan and polycarbonate. Artificial Organs 1982;6(3):324-7. [MEDLINE: 6217802]
296. Stefanovic V, Vlahovic P, Kostic S, Mitic-Zlatkovic M. In vitro blood compatibility evaluation of cuprophan and polyacrylonitrile membranes. Nephron 1998;79(3):350-1. [MEDLINE: 9678440]
297. Stegmayr BG, Esbensen K, Gutierrez A, Lundberg L, Nielsen B, Stroemsaeter CE, et al. Granulocyte elastase, beta-thromboglobulin, and C3d during acetate or bicarbonate hemodialysis with Hemophan compared to a cellulose acetate membrane. International Journal of Artificial Organs 1992;15(1):10-8. [MEDLINE: 1532382]
298. Stegmayr BG, Hussain A. Serum Beta2- Microglobulin increases during HD with a hemophane but not with a cellulose diacetate dialyzer [abstract]. International Journal of Artifical Organs 1998;21(10):634. [CENTRAL: CN-00322004]
299. Stegmayr BG, Almroth G, Berlin G, Fehrman I, Kurkus J, Norda R, et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. International Journal of Artificial Organs 1999;22(2):81-7. [MEDLINE: 10212042]
300. Stegmayr BG, Almroth G, Kurkus J, Olander R, Sterner G, Thysell H, et al. Plasma exchange versus immunoadsorption in the treatment of rapidly progressive glomerulonephritis (rpg). A multi-center study [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:294.
301. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrology Dialysis Transplantation 2001;16(5):999-1008. [MEDLINE: 11328907]
302. Stuard S, Bonomini M, Santarelli P, Carreno MP, Settefrati N, Tetta C, et al. Cell-associated and soluble adhesion molecules during hemodialysis with synthetic membranes. Giornale Italiano Di Nefrologia 1996;13(3):175-85. [EMBASE: 1996169305]
303. Sultan Y, London GM, Goldfarb B, Toulon P, Marchais SJ. Activation of platelets, coagulation and fibrinolysis in patients on long-term haemodialysis: influence of cuprophan and polyacrylonitrile membranes. Nephrology Dialysis Transplantation 1990;5(5):362-8. [MEDLINE: 2142756]
304. Takenaka T, Itaya Y, Tsuchiya Y, Kobayashi K, Suzuki H. Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis. Blood Purification 2001;19(1):10-4. [MEDLINE: 11114571]
305. Takenaka T, Kobayashi K, Suzuki H. Warning of high-flux hemodialysis. Renal Failure 2001;23(6):819-25. [MEDLINE: 11777321]
306. Tayeb JS, Provenzano R, El-Ghoroury M, Bellovich K, Khairullah Q, Pieper D, et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. American Journal of Kidney Diseases 2000;35(4):606-10. [MEDLINE: 10739779]
307. Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch JJ. Effect of dialyzer geometry during hemodialysis with cuprophane membranes. Kidney International 1992;42(2):442-7. [MEDLINE: 1405328]
308. Tessitore N, Lapolla A, Arico N, Gammaro L, Bedogna V, Valenti G, et al. Effect of BKF polymethylmethacrylate hemodialysis (hd) on plasma pentosidine (pe) levels [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):178A.
309. Tessitore N, Lapolla A, Arico NC, Poli A, Gammaro L, Bassi A, et al. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. Journal of Nephrology 2004 Sep;17(5):707-14. [MEDLINE: 15593039]
310. Thalhammer F, Kletzmayr J, El Menyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, et al. Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers. American Journal of Kidney Diseases 1998;32(4):642-5. [MEDLINE: 9774127]
311. Thijs A, Grooteman MP, Zweegman S, Nube MJ, Huijgens PC, Stehouwer CD. Platelet activation during haemodialysis: comparison of cuprammonium rayon and polysulfone membranes. Blood Purification 2007;25(5-6):389-94. [MEDLINE: 17890860]
312. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, Manns B, Alberta Kidney Disease Network. Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. American Journal of Kidney Diseases 2009; Vol. 54, issue 6:1108-15. [MEDLINE: 19619920]
313. Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, et al. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial. American Journal of Kidney Diseases 2008;51(5):796-803. [MEDLINE: 18436090]
314. Wang W, Tonelli M, Hemmelgarn B, Taub K, Johnson J, Manns BJ. Increasing small solute clearance in underdialysed large hemodialysis patients does not improve quality of life: a randomized cross-over study [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):867A.
315. Traut M, Haufe CC, Eismann U, Deppisch RM, Stein G, Wolf G. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. [see comment]. Blood Purification 2007;25(5-6):432-40. [MEDLINE: 17957097]
316. Deteix P, Betail G, Tridon A, Gaillard G, Marques-Verdier A, Cluzel P, et al. Histamine release during hemodialysis [abstract]. Kidney International 1987;32:427.
317. Tridon A, Deteix P, Coves G, Cluzel P, Marqués Verdier A, Wauquier JP, et al. Evaluation of the biocompatibility of a new cellulose membrane by studying the complement system and histamine liberation [Evaluation de la biocompatibilité d'une nouvelle membrane cellulosique par l'étude du système du complément et de l'histaminolibération]. Néphrologie 1987;8(4):217-21. [MEDLINE: 2447516]
318. Valentijn RM. Aluminum removal: AN69-S membrane versus a combined cuprophane and charcoal filter. Kidney International 1988;24(Suppl):S171. [MEDLINE: 3163041]
319. Vanherweghem JL, Leon M, Goldman M, Lietar N, Gamar N, Thayse C. Membrane-related eosinophilia in hemodialysis. Kidney International - Supplement 1988;24:S73-4. [MEDLINE: 3163056]
320. Vanholder RC, Sys E, DeCubber A, Vermaercke N, Ringoir SM. Performance of cuprophane and polyacrylonitrile dialyzers during multiple use. Kidney International - Supplement 1988;24:S55-6. [MEDLINE: 3163053]
321. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney International 1991;39l(2):320-7. [MEDLINE: 2002645]
322. Vanholder R, Van Haecke E, Veys N, Ringoir S. Endotoxin transfer through dialysis membranes: small- versus large-pore membranes. Nephrology Dialysis Transplantation 1992;7(4):333-9. [MEDLINE: 1317524]
323. Vanholder R, Lameire N. Does biocompatibility of dialysis membranes affect recovery of renal function and survival?. Lancet 1999;354(9187):1316-8. [MEDLINE: 10533855]
324. Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO Journal 1995;41(3):M713-6. [MEDLINE: 8573899]
325. van Ypersele de Strihou C, Jadoul M, Jamart J. Highly permeable and biocompatible membranes. Lancet 1991;337(8754):1415-6. [MEDLINE: 1674789]
326. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney International 1991;39(5):1012-9. [MEDLINE: 2067196]
327. Varela MP, Kimmel PL, Phillips TM, Mishkin GJ, Lew SQ, Bosch JP. Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purification 2001;19(4):370-9. [MEDLINE: 11574733]
328. Vaslaki L, Weber C, Mitteregger R, Falkenhagen D. No difference in cytokine induction between patients on on-line hemodiafiltration (HDF) and low-flux HD [abstract]. International Journal Artificial Organs 1998;21(10):609. [CENTRAL: CN-00321994]
329. Velasquez MT, von Albertini B, Lew SQ, Mishkin GJ, Bosch JP. Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis. American Journal of Kidney Diseases 1998;31(4):618-23. [MEDLINE: 9531177]
330. Verbeelen D, Jochmans K, Herman AG, Van der Niepen P, Sennesael J, De Waele M. Evaluation of platelets and hemostasis during hemodialysis with six different membranes. Nephron 1991;59(4):567-72. [MEDLINE: 1766495]
331. Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990;336(8727):1360-2. [MEDLINE: 1978172]
332. Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney International 1994;45(5):1497-503. [MEDLINE: 8072263]
333. Wakasa M, Akizawa T, Kinugasa E, Koshikawa S. Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitor. Clinical Nephrology 1995;44 Suppl 1:S29-32. [MEDLINE: 8608658]
334. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrology Dialysis Transplantation 2004;19(10):2570-5. [MEDLINE: 15280524]
335. Ward RA, Schaefer RM, Falkenhagen D, Joshua MS, Heidland A, Klinkmann H, et al. Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis. Nephrology Dialysis Transplantation 1993;8(1):47-53. [MEDLINE: 8381935]
336. Ward RA, Buscaroli A, Schmidt B, Stefoni S, Gurland HJ, Klinkmann H. A comparison of dialysers with low-flux membranes: significant differences in spite of many similarities. Nephrology Dialysis Transplantation 1997;12(5):965-72. [MEDLINE: 9175051]
337. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. Journal of the American Society of Nephrology 2000;11(12):2344-50. [MEDLINE: 11095657]
338. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney International 2003;63(1):353-9. [MEDLINE: 12472803]
339. Wei SS, Paganini EP, Cressman, Wright E. Use of hemodiafiltration to enhance delivered dialysis. ASAIO Journal 1994;40(4):977-80. [MEDLINE: 7858335]
340. Wens R, Dratwa M. Intact parathormone (PTH) clearance with high-flux HD membranes [abstract]. Nephrology Dialysis Transplantation 1992;7:166. [CENTRAL: CN-00260683]
341. Woffindin C, Hoenich NA, Matthews JN. Cellulose-based haemodialysis membranes: biocompatibility and functional performance compared. Nephrology Dialysis Transplantation 1992;7(4):340-5. [MEDLINE: 1317525]
342. Woo YM. Dialysis with biocompatible membranes may delay recovery of graft function following renal transplantation [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):719A.
343. Woo YM, Craig AM, King BB, Junor BJ, McMillan MA, Briggs JD, et al. Biocompatible membranes do not promote graft recovery following cadaveric renal transplantation. Clinical Nephrology 2002;57(1):38-44. [MEDLINE: 1841067]
344. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrology Dialysis Transplantation 2000;15 Suppl 1:36-42. [MEDLINE: 10737165]
345. Wright MJ, Woodrow G, Umpleby S, Hull S, Brownjohn AM, Turney JH. Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis. American Journal of Kidney Diseases 1999;34(1):36-42. [MEDLINE: 10401013]
346. Wright MJ, Woodrow G, Young G, Brownjohn AM, Turney JH. Biocompatible dialysis membranes do not reduce plasma leptin levels. Nephrology Dialysis Transplantation 2000;15(6):925-6. [MEDLINE: 10831667]
347. Yasuhiro I, Eiichi N, Mineo O, Muneto Y, Toshihiro I, Masahiro F, et al. Removal of serum beta-2 microglobulin using high-performance membranes and analysis of changes in serum BMG levels after dialysis. American Journal of Nephrology 1998;18(3):228-32. [MEDLINE: 9627039]
348. Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Kidney International 1990;38(5):962-8. [MEDLINE: 2266681]
349. Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney International 1991;39(5):1020-6. [MEDLINE: 2067197]
350. Zaoui P, Hakim RM. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney International 1993;43(6):1298-305. [MEDLINE: 8315942]
351. Zhang DL, Liu J, Cui WY, Ji DY, Zhang Y, Liu WH. Differences in bio-incompatibility among four biocompatible dialyzer membranes using in maintenance hemodialysis patients. Renal Failure 2011; Vol. 33, issue 7:682-91. [MEDLINE: 21787159]
352. NCT00004285. Phase II randomized study of standard vs high amount of hemodialysis using low vs high flux dialyzer membranes for end stage renal disease. clinicaltrials.gov/ct2/show/NCT00004285 (accessed 10 Nov 2012).
353. Wanner C, Krane V, März W, Olschewski M, Mann J F, Ruf G et a l. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine 2005;353(3):238-48. [MEDLINE: 16034009]
354. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine 2009;360(14):1395-407. [MEDLINE: 19332456]
355. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584-90. [MEDLINE: 9718377]
356. CARI Guidelines. Caring for Australasians with Renal Impairment. http://www.cari.org.au/DIALYSIS_adequacy_published/dialysis_membranes_jul-2005.pdf Accessed 28 February 2011.
357. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. In-center hemodialysis six times per week versus three times per week. New England Journal of Medicine 2010;363(24):2287-300. [MEDLINE: 21091062]
358. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney International 1999;56(6):2005-15. [MEDLINE: 10594776]
359. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782-9. [MEDLINE: 19861670]
360. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
361. European Best Practice Guidelines Group. II.2 Haemodialysis dose quantification: middle molecules (MM). Nephrology Dialysis and Transplantation 2002;17(Suppl 7):21-3.
362. US Food, Drug Administration. Guidance for the industry and CDRH reviewers on the content of premarket notifications for conventional and high permeability hemodialyzers. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080165.htm Accessed 7 May 2010.
363. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [MEDLINE: 12111919]
364. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
365. Jaber BL, Gonski JA, Cendoroglo M, Balakrishnan VS, Razeghi P, Dinarello CA, et al. New polyether sulfone dialyzers attenuate passage of cytokine-inducing substances from pseudomonas aeruginosa contaminated dialysate. Blood Purification 1998;16(4):210-9. [PUBMED: 9736790]
366. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative 2006 Updates Clinical Practice Guidelines and Recommendations Hemodialysis Adequacy. http://www.kidney.org/professionals/kdoqi/pdf/12-50-0210_JAG_DCP_Guidelines-HD_Oct06_SectionA_ofC.pdf Accessed 19 March 2011.
367. Lonnemann G, Behme TC, Lenzner B, Floege J, Schulze M, Colton CK, et al. Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria. Kidney international 1992;42(1):61-8. [PUBMED: 1635355]
368. MacLeod AM, Campbell M, Cody JD, Daly C, Donaldson C, Grant A, et al. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003234.pub2]
369. Miskulin D, Bragg-Gresham J, Gillespie BW, Tentori F, Pisoni RL, Tighiouart H, et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clinical Journal of the American Society of Nephrologists 2009;4(11):1818-26. [MEDLINE: 19808231]
370. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. American Journal of Kidney Diseases 2001;37(2):276-86. [MEDLINE: 11157367]
371. Rabindranath KS, Strippoli GFM, Roderick P, Wallace SA, MacLeod AM, Daly C. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. American Journal of Kidney Diseases 2005;45(3):437-47.
372. Renal Association Clinical Practice Guidelines. Haemodialysis membranes (Guidelines 4.1 to 4.5). http://www.renal.org/clinical/GuidelinesSection/Haemodialysis.aspx Accessed 19 March 2011.
373. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Seminars in Dialysis 2011;24(1):1-4. [MEDLINE: 21299628]
374. Schwarz A, Keller F, Seyfert S, Poll W, Molzahn M, Distler A. Carpal tunnel syndrome: a major complication in long-term hemodialysis patients. Clinical Nephrology 1984;22(3):133-7. [MEDLINE: 6488595]
375. Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van Biesen W. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2010;25(4):1230-2. [PUBMED: 20028829]
376. United States Renal Data System Annual Data Report 2010. www.usrds.org Accessed 21 February 2011; Vol. Volume 2 Atlas of ESRD.
377. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. American Journal of Kidney Diseases 1991;39(5):1012-9. [MEDLINE: 2067196]
378. Woffindin C, Hoenich NA. Blood-membrane interactions during haemodialysis with cellulose and synthetic membranes. Biomaterials 1988;9(1):53-7. [PUBMED: 3126842]
379. Rabindranath KS, Strippoli GFM, Daly C, Roderick PJ, Wallace SA, MacLeod AM. High-flux versus low-flux haemodialysis membranes for end-stage renal disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD005016]